Prostate Cell News 9.46 November 30, 2018 | |
| |
TOP STORYONECUT2 Is a Targetable Master Regulator of Lethal Prostate Cancer That Suppresses the Androgen Axis ONECUT2 acted as a survival factor in metastatic castration-resistant prostate cancer models, suppressed the androgen receptor (AR) transcriptional program by direct regulation of AR target genes and the AR licensing factor FOXA1, and activated genes associated with neural differentiation and progression to lethal disease. [Nat Med] Abstract | Press Release | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Chromatin Remodeling ATPase BRG1 and PTEN Are Synthetic Lethal in Prostate Cancer Phosphatase and tensin homolog (PTEN) loss stabilized BRG1 protein through the inhibition of the AKT-GSK3β-FBXW7 axis. Increased BRG1 expression in PTEN-deficient prostate cancer cells led to chromatin remodeling into configurations that drove a protumorigenic transcriptome, causing cells to become further addicted to BRG1. [J Clin Invest] Abstract | Full Article TRIM28 Protects TRIM24 from SPOP-Mediated Degradation and Promotes Prostate Cancer Progression Scientists report TRIM28 as a critical upstream regulator of TRIM24. TRIM28 protein interacted with TRIM24 to prevent its ubiquitination and degradation by SPOP. TRIM28 promoted prostate cancer cell proliferation in vitro and xenograft tumor growth in vivo. [Nat Commun] Full Article Glucose-6-phosphate isomerase (GPI) maintained glucose metabolism and energy homeostasis in hypoxia by redirecting the glucose flux from androgen/AR-dependent pentose phosphate pathway to the hypoxia-induced glycolysis pathway, thereby reducing the growth inhibitory effect of enzalutamide. Inhibiting GPI overcame therapy resistance in hypoxia in vitro and increased enzalutamide efficacy in vivo. [Nat Commun] Full Article Cell Fate Regulation by Reticulon-4 in Human Prostate Cancers Lentivirus-mediated reticulon-4 (RTN4) overexpression potently inhibited DU145 and LNCaP cells proliferation. The cell cycle was blocked in the G2/M phase and significant cell senescence was observed in RTN4 overexpressed prostate cancer cells. [J Cell Physiol] Abstract Spheroids were cultured in a modified stem cell medium and characterized by a live/dead assay, whole-spheroid immunohistochemistry and PSA-measurements in culture medium. Their response to pharmaceutical treatment with docetaxel, bicalutamide, enzalutamide and abiraterone was tested. [J Cancer Res Clin Oncol] Abstract After the treatment with bisphenol A (BPA) for 24 hours, cell viability was decreased significantly with increased cell apoptosis in two cell lines. Moreover, both PC-3 and LNCaP cells had reduced expression level of cAMP, cystic fibrosis transmembrane conductance regulator, and adenosine triphosphate upon BPA treatment. [J Cell Biochem] Abstract Investigators found that POU3F3 and rho-associated protein kinase 1 (ROCK1) were both increased in tumor tissues than in adjacent healthy tissues of patients with prostate carcinoma. POU3F3 and ROCK1 overexpression promoted, while ROCK1 knockdown inhibited the proliferation of prostate carcinoma cells. [J Cell Biochem] Abstract Researchers investigated the effects of miR-30e and its target gene, M3 muscarinic acetylcholine receptor (CHRM3), on the adhesion, migration, invasion and cell cycle distribution of prostate cancer cells via the mitogen-activated protein kinase (MAPK) signaling pathway. [Int J Oncol] Abstract Subscribe to one of our other 19 science newsletters such as Mammary Cell News & ESC & iPSC News. | |
| |
REVIEWSProstate-Specific Markers to Identify Rare Prostate Cancer Cells in Liquid Biopsies Using epithelial markers to accurately detect circulating tumor cells and bone marrow-derived disseminated tumor cells is associated with difficulties, and prostate-specific markers are needed for the detection of these cells using rare cell assays. [Nat Rev Urol] Abstract Visit our reviews page to see a complete list of reviews in the prostate cell research field. | |
| |
INDUSTRY NEWSForesee Pharmaceuticals Co., Ltd. announced that all patients had completed participation in its Phase III, multinational, multicenter trial of FP-001/LMIS 25 mg, a three-month, ready-to-use subcutaneous depot formulation for the treatment of advanced prostate cancer. [Foresee Pharmaceuticals Co., Ltd.] Press Release ERC Awards €573 Million to Mid-Career Researchers from 40 Countries The European Research Council (ERC) announced the recipients of its Consolidator Grant competition: 291 top scientists across Europe. Funding for these researchers, part of the Horizon 2020 research and innovation program, is worth in total €573 million and will give them a chance to build up their teams and have far-reaching impact. [The European Research Council] Press Release | |
| |
POLICY NEWSNIH Director Says There’s Work to Do on Regulating Genome Editing Globally The apparent birth this month of the first genetically modified babies is “a lesson in the potential for human hubris to overtake us,” Dr. Francis Collins, the director of the National Institutes of Health (NIH), told STAT, but he said there is little U.S. officials can do to influence how China sanctions the rogue scientist who claims to have led the ethically dubious scientific breakthrough. [STAT News] Editorial Does Science Have a Bullying Problem? A spate of bullying allegations have rocked several high-profile science institutions. Here’s how researchers, universities, funders and others are dealing with the issue. [Nature News] Editorial Some Research May Be Encouraging Ineffective Prescriptions, Says New Study A new paper published by McGill University researchers in JAMA Internal Medicine suggests that some clinical trials may promote the use of ineffective and costly treatments. That’s the opposite of what clinical trials are aimed at, namely preventing ineffective and costly treatments from being taken up by physicians and patients. [McGill University] Editorial
| |
EVENTSNEW ICPCCR 2019: 21st International Conference on Prostate Cancer and Cancer Research Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Tenure-Track/Tenured Faculty Position – Cancer Biology (University of Chicago) Postdoctoral Associate – Molecular and Cell Biology (Baylor College of Medicine) Postdoctoral Fellow – Advanced Prostate Cancer Research (Cleveland Clinic) Posdoctoral Position – Prostate Cancer Research (Louisiana State University Health Sciences Center) Postdoctoral Fellow – Cancer Immunotherapy (University of Notre Dame) Postdoctoral Position – Prostate Cancer (The University of Minnesota, Twin Cities) Research Fellow – Prostate Cancer (Sechenov University) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Prostate Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|